Strasbourg-based RDS, a French MedTech firm, immediately introduced a €14 million Sequence A funding spherical for its distant monitoring and wearable patch, to be able to speed up its improvement in France, Germany and the broader European market.

The SPI (Sociétés de Projets Industriels) fund, managed on behalf of the French state by Bpifrance, led the spherical, with Vital Path Ventures additionally taking a brand new stake. MACSF, Capital Grand Est and different historic traders additionally contributed.

With this financing, RDS may have raised a complete of €28 million since its founding. The Sequence A €14 million comes on high of the €14 million in capital and non-dilutive financing offered by the French authorities, notably by the France 2030 funding plan.

“This funding offers us the means to ramp up our gross sales progress in Europe, consolidate the scientific and well being financial worth of MultiSense, and prepare for market launch in North America,” mentioned Elie Lobel, CEO of RDS.

He added: “These funds imply we will roll out our answer extra extensively to hospitals, develop its constructive influence for sufferers and care groups, and supply dependable, steady, clinically validated distant monitoring to as many amenities as attainable. The funds raised are a testomony to our traders’ enduring confidence on this challenge and the staff.”

Based in 2020, RDS specialises in distant affected person monitoring, creating, manufacturing and advertising and marketing MultiSense, a distant medical monitoring answer. RDS depends on a global staff and collaborates with main analysis tasks comparable to DARE and 5G-OR. Incubated at SEMIA/Quest for Well being and accelerated by PariSanté Campus, it goals to redefine telemonitoring requirements by patented know-how and an eco-conscious method.

The MultiSense answer combines a wearable patch with a cloud-based platform and related assist providers. It repeatedly screens six key parameters, together with coronary heart charge, respiratory charge and oxygen saturation.

From the outset, sustainability has been a core focus: the system will be cleaned, refurbished and reused to minimise its carbon footprint. MultiSense is designed to assist the implementation of short-stay hospitalisation protocols, aiming to assist cut back the typical size of hospital stays, to make sure safer hospital discharge and to enhance sufferers’ high quality of life.

“France 2030 is proud to have supported this challenge since 2020 and to work immediately with SPI on the speedy industrialisation and efficient deployment of the answer for the advantage of sufferers. RDS’ story clearly reveals how France 2030 is able to transitioning a challenge from the lab stage to turning into a global champion,” mentioned Bruno Bonnell, Secretary Basic for Funding, accountable for France 2030.

RDS’ Sequence A suits right into a broader surge of funding flowing into European HealthTech in 2025. In line with our earlier protection, HealthTech was essentially the most funded tech sector in Q1 2025 (bringing in €4.42 billion in personal funding). Two related developments start to rise when contemplating different funding rounds on this sector:

• Wearable/monitoring/system scale: ViCentra’s €72.4 million Sequence D spherical underscores how differentiated medical gadgets (in that case, insulin patch pumps) are attracting important capital once they mix usability, regulatory readiness, and scientific integration.

• Imaging and diagnostic instruments: Rounds comparable to PIUR IMAGING’s progress capital present that AI-augmented imaging and diagnostic gadgets are additionally drawing sustained investor curiosity, particularly when bridging into new geographies.

Relative to those, RDS’ increase is average in dimension however significant, particularly for a Sequence A within the MedTech {hardware} + scientific trials house. Its concentrate on scaling industrialisation, reimbursement, and European rollout is carefully aligned with what traders have rewarded elsewhere.

“We’re delighted to be supporting RDS on this crucial part of its improvement,” mentioned Magali Joëssel, director of the SPI fund at Bpifrance. “This funding offers the corporate the means to turn into a number one participant in post-operative distant monitoring by MultiSense, and a pioneer within the medication of the longer term. By scaling the manufacturing of its answer, RDS totally embodies the precept of the SPI fund: funding the industrialisation of revolutionary applied sciences that may convey progress and jobs to France.”

Their clinically validated know-how has already been rolled out in 15 hospitals throughout France, Belgium and Germany. Within the final yr, the system was added to the authorised provides listing for RESAH and UniHA, main public buying our bodies for hospitals in France.

The corporate expects to create a number of hundred new jobs by 2035, bolstering its gross sales staff to satisfy the demand for the MultiSense answer. The funds can even finance the industrialisation of the answer that’s manufactured in France, with the purpose of steadily ramping up manufacturing and refurbishing capacities.

Concurrently, RDS will launch complementary scientific trials to assist its functions for reimbursement in France and throughout Europe. The corporate can also be getting ready to provoke the FDA registration course of, with a view to a US market launch in 2028.

“We consider that the important thing to remodeling the healthcare system is beneficial innovation and industrial ambition,” mentioned Nicolas Foessel of Vital Path Ventures. “With our funding in RDS, we’re backing a staff that mixes technological excellence with scientific influence and a long-term imaginative and prescient for medication, with emphasis on a extra preventive, smoother and human method. MultiSense exemplifies this positioning, enabling steady monitoring and assembly sufferers’ explicit wants away from the hospital setting.”

In parallel with this funding spherical, Laurent Monnin, senior funding director at Bpifrance, joins the corporate’s strategic board, as does Nicolas Foessel, representing Vital Path Ventures.

“The funding offered by SPI and Vital Path Ventures is an actual asset for RDS, which is able to be capable of ramp-up actions after a launch part to which MACSF and Capital Grand Est have contributed,” mentioned Jean-François Rax, companion at Capital Grand Est.